Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignanc...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019-10-01
|
| סדרה: | Oncology Reviews |
| נושאים: | |
| גישה מקוונת: | https://www.oncologyreviews.org/index.php/or/article/view/425 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|